ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD37/DM1 Derivative Antibody-drug Conjugate Debio 1562M

Its studies are mostly in Leukemia, Myeloid, Acute, led by Debiopharm.

Furthest: phase 2, since May 5, 20251 company-led study, 1 open or runningNext primary completion: Nov 2031 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Debiopharm11 open or runningphase 2since May 5, 2025May 5, 2025Nov 2031phase 2 · NCT06969430

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 5, 2025First study: phase 2 study in Leukemia, Myeloid, AcuteFirst studyNCT06969430 · 154 planned · United States

Ahead

  1. Nov 2031Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT06969430

TargetBeta

CD37 →read by rule
“An antibody-drug conjugate (ADC) composed of naratuximab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) CD37, covalently ”NCIt, by rule

Other programs on CD37

ProgramCompanyFurthest phaseStudies
Anti-CD37/DXd Antibody-drug Conjugate DS3790ruleDaiichi Sankyophase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06969430Leukemia, Myeloid, Acute · United States2RecruitingNov 2031154

How it is read

Names in the registry

  • “Debio 1562M”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.